Surge
Surge provides a clinical test that identifies surgical patients at high risk of postoperative infections so care teams can intervene earlier and tailor discharge and monitoring. The company converts single‑cell and multiomics immune profiles into actionable risk scores using its Stabl biological fingerprinting technology and machine‑learning models. Its flagship product, PreCyte (PreCyte SSI), applies mass cytometry/single‑cell omics and systems‑biology analytics to simulate surgical immune responses from a small blood sample. Surge operates as a precision‑medicine B2B SaaS offering to hospitals and surgical teams, with early clinical deployments at academic medical centers. The platform targets perioperative risk stratification, personalized care pathways, and diagnostics-driven prevention in surgical populations.
Surge
Surge provides a clinical test that identifies surgical patients at high risk of postoperative infections so care teams can intervene earlier and tailor discharge and monitoring. The company converts single‑cell and multiomics immune profiles into actionable risk scores using its Stabl biological fingerprinting technology and machine‑learning models. Its flagship product, PreCyte (PreCyte SSI), applies mass cytometry/single‑cell omics and systems‑biology analytics to simulate surgical immune responses from a small blood sample. Surge operates as a precision‑medicine B2B SaaS offering to hospitals and surgical teams, with early clinical deployments at academic medical centers. The platform targets perioperative risk stratification, personalized care pathways, and diagnostics-driven prevention in surgical populations.